<DOC>
	<DOCNO>NCT00759460</DOCNO>
	<brief_summary>The purpose exploratory study evaluate effect sertindole olanzapine metabolic parameter syndrome patient schizophrenia .</brief_summary>
	<brief_title>Study Metabolic Parameters Sertindole Patients With Schizophrenia</brief_title>
	<detailed_description>The prevalence metabolic syndrome estimate around 20-25 % population particularly high patient schizophrenia . Individuals metabolic syndrome twice likely die , three time likely suffer heart attack stroke compare individual without syndrome . Patients atypical antipsychotic medication consider high risk group diabetes cardiovascular disease . Weight gain common patient take neuroleptics atypical antipsychotic , excessive body weight risk factor type 2 diabetes .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Sertindole</mesh_term>
	<criteria>Patients schizophrenia Participation 11286 study Capable complete studyrelated activity duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>